Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage

Int J Mol Sci. 2017 Jan 18;18(1):188. doi: 10.3390/ijms18010188.


The highly reactive dicarbonyl methylglyoxal (MGO) is mainly formed as byproduct of glycolysis. Therefore, high blood glucose levels determine increased MGO accumulation. Nonetheless, MGO levels are also increased as consequence of the ineffective action of its main detoxification pathway, the glyoxalase system, of which glyoxalase 1 (Glo1) is the rate-limiting enzyme. Indeed, a physiological decrease of Glo1 transcription and activity occurs not only in chronic hyperglycaemia but also with ageing, during which MGO accumulation occurs. MGO and its advanced glycated end products (AGEs) are associated with age-related diseases including diabetes, vascular dysfunction and neurodegeneration. Endothelial dysfunction is the first step in the initiation, progression and clinical outcome of vascular complications, such as retinopathy, nephropathy, impaired wound healing and macroangiopathy. Because of these considerations, studies have been centered on understanding the molecular basis of endothelial dysfunction in diabetes, unveiling a central role of MGO-Glo1 imbalance in the onset of vascular complications. This review focuses on the current understanding of MGO accumulation and Glo1 activity in diabetes, and their contribution on the impairment of endothelial function leading to diabetes-associated vascular damage.

Keywords: glyoxalase; insulin-resistance; methylglyoxal; vascular function.

Publication types

  • Review

MeSH terms

  • Animals
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Humans
  • Insulin Resistance
  • Lactoylglutathione Lyase / metabolism*
  • Models, Biological
  • Pyruvaldehyde / metabolism
  • Vascular Diseases / enzymology*


  • Pyruvaldehyde
  • Lactoylglutathione Lyase